

References for Cholera Vaccines: WHO Position Paper, August 2017

References with abstracts cited in the position paper in the order of appearance.

WER, No. 13, 2010, pp.117-128.

No abstract available.

WER No. 22, 2017, pp. 301–320.

No abstract available.

Background Paper on Whole-Cell, Killed, Oral Cholera Vaccines.

http://www.who.int/immunization/sage/meetings/2017/april/OCV_Background_Document_SageWG_FinalVersion_EditedPS_.pdf?ua=1, accessed May 2017.

No abstract available.

Interim Guidance Document on Cholera Surveillance.

http://www.who.int/cholera/task_force/GTFCC-Guidance-cholera-surveillance.pdf?ua=1, accessed July 2017.

No abstract available.

Sauvageot D et al. Cholera Incidence and Mortality in Sub-Saharan African Sites during Multi-country Surveillance. PLoS Negl Trop Dis. 2016;10(5): e0004679.

Rebaudet S et al. Cholera in Africa: Microbiology, Epidemiology, Prevention and Control. J Infect Dis. 2013; 208:S1-S3.

Nair G. Cholera Outbreaks. Current Topics in Microbiology and Immunology. 2014;379:1-258.

WER, No. 38, 2015, pp. 433-440.

No abstract available.

Ali M et al. Updated Global Burden of Cholera in Endemic Countries. PLoS Negl Trop Dis 2015;9: e0003832

Bi Q et al. Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2017; S1473-3099(17):30359-6.

Deen JL et al. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Neglected Trop Dis. 2008; 2(2):e173.

Zuckerman JN et al. The true burden and risk of cholera: implications for prevention and control. Lancet Infect Dis. 2007;7(8):521-30.

Clemens JD et al. Cholera vaccines. Chapter 14, In: Vaccines, 7th edition. Edited by Plotkin SA, Orenstein WA, Offit PA, Philadelphia,PA: WB Saunders Company, 2017

No abstract available.

Steffen R et al. Cholera: assessing the risk to travelers and identifying methods of protection. *Travel Medicine and Infectious Disease*. 2003;1:80-88

Sack DA. Cholera vaccine in refugee settings. *JAMA*. 1998;280:600 – 2 .

International Coordinating Group (ICG) on Vaccine Provision.
<http://www.who.int/csr/disease/icg/en/>, accessed May 2017.
No abstract available.

The Global Task Force on Cholera Control.
http://www.who.int/cholera/task_force/en/, accessed May 2017.
No abstract available.

Mukhopadhyay AK et al. Cholera outbreaks in the El Tor biotype era and the impact of the new El Tor variants. *Curr Top Microbiol Immunol*.2014;379:17-47.

Nair GB et al. Cholera due to altered El Tor strains of *Vibrio cholerae* O1 in Bangladesh. *J Clin Microbiology*. 2006;44:4211-13.

Ansaruzzaman M et al. Genetic diversity of El Tor strains of *Vibrio cholera* O1with hybrid traits isolated from Bangladesh and Mozambique. *Int J Med Microbiol*. 2007;297(6):443-9.

Siddique AK et al. El Tor cholera with severe disease: a new threat to Asia and beyond. *Epidemiol Infect*. 2009;14:1-6.

Glass RI et al. Protection against Cholera in Breast-Fed Children by Antibodies in Breast Milk. *N Engl J Med*.1983;308:1389-1392.

Merrell DS et al. Host-induced epidemic spread of the cholera bacterium. *Nature*. 2002;417(6889):642-645.

WHO. The treatment of diarrhoea : a manual for physicians and other senior health workers. 2005. Available:
<http://apps.who.int/iris/bitstream/10665/43209/1/9241593180.pdf>, accessed June 2017.
No abstract available.

Guidelines for the inpatient treatment of severely malnourished children. Geneva, WHO, 2003. http://www.who.int/nutrition/publications/guide_inpatient_text.pdf, accessed July 2017.
No abstract available.

WHO guidelines on Cholera. Available: <http://www.who.int/cholera/en/>, accessed May 2017.

No abstract available.

UNICEF Cholera: case management. Available:

https://www.unicef.org/cholera/index_71220.html, accessed May 2017.

No abstract available.

Cross R et al. Revisiting doxycycline in pregnancy and early childhood – time to rebuild its reputation? Expert Opinion on Drug Safety.2016;15(3):367-382.

No abstract available.

Sack DA et al. Antimicrobial resistance in shigellosis, cholera and campylobacteriosis. WHO report, 2001; (WHO/CDS/SCR/DRS/2001.8).

http://www.who.int/drugresistance/Antimicrobial_resistance_in_shigellosis_cholera_and_cam.pdf, accessed May 2017

No abstract available.

Water, sanitation and hygiene (WASH). Available:

www.unicef.org/cholera/index_71218.html, accessed May 2017.

No abstract available.

WHO, Cholera Outbreak: Assessing the Outbreak Response and Improving Preparedness.2004. Available:

<http://www.who.int/cholera/publications/final%20outbreak%20booklet%20260105-OMS.pdf>, accessed July 2017.

No abstract available.

Leung DT et al. Immune responses to cholera in children. Expert Rev Anti Infect Ther. 2012;10(4): 435–444.

Pasetti MF et al. Insights from Natural Infection-Derived Immunity to Cholera Instruct Vaccine Efforts. Clin Vaccine Immunol. 2012;19.(11):1707-1711.

Ali M et al. Natural cholera infection-derived immunity in an endemic setting. J. Infect. Dis. 2011;204:912–918.

Clemens JD et al. Biotype as determinant of natural immunising effect of cholera. Lancet. 1991;337:883–884.

Levine MM et al. Duration of infection-derived immunity to cholera. J. Infect. Dis. 1981;143:818–820

Dukoral. Summary of Product Characteristics.

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000476/WC500037570.pdf, accessed May 2017.

No abstract available.

Euvichol. Package Insert.

http://www.eubiologics.com/en/products/Euvichol_insert.pdf, accessed May 2017.

No abstract available.

Shanchol. Prescribing Information.

http://www.who.int/immunization_standards/vaccine_quality/pq_250_cholera_1dose_shantha_insert.pdf?ua=1, accessed May 2017.

No abstract available.

Vaxchora, package insert, available:

<https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM506235.pdf>, accessed June 2017.

No abstract available.

Background paper on the integration of oral cholera vaccines into global cholera control programmes, presented to the WHO SAGE in October 2009.

www.who.int/entity/immunization/sage/1_Background_Paper_Cholera_Vaccines_FIN_ALdraft_13_oct_v2.pdf, accessed May 2017.

No abstract available.

Ryan ET et al. Cholera Vaccines. J Travel Med. 2001;8(2):82-91.

No abstract available.

Dukoral. Annex 1. Summary of Product

Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000476/WC500037570.pdf, accessed July 2017.

No abstract available.

Guidelines for the production and control of inactivated oral cholera vaccines TRS 924, 2004, Annex 3.

<http://www.who.int/biologicals/publications/trs/areas/vaccines/cholera/129-149.pdf>, accessed July 2017.

No abstract available.

Cholera Vaccines Background Paper.

www.who.int/entity/immunization/sage/1_Background_Paper_Cholera_Vaccines_FIN_ALdraft_13_oct_v2.pdf, accessed July 2017

No abstract available.

Kanungo S et al. Flexibility of Oral Cholera Vaccine Dosing—A Randomized Controlled Trial Measuring Immune Responses Following Alternative Vaccination Schedules in a Cholera Hyper-Endemic Zone. PLoS Negl Trop Dis. 2015;9(3): e0003574

Saha A et al. The oral cholera vaccine Shanchol™ when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants. Vaccine. 2016;34(13): 1551-1558.

Luquero FJ et al. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012. *PLoS Negl Trop Dis*. 2013;7(10):e2465.

Clemens JD et al. Field trial of oral cholera vaccines in Bangladesh. *Lancet*. 1986;19:124-7.

Van Loon FPL et al. Field trial of inactivated cholera vaccines in Bangladesh: results from 5 years of follow-up. *Vaccine*.1996;14(2):162-166.

Clemens JD et al. Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera. *Lancet*.1988; 18(1):1375-1379.

Sanchez JL et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. *Lancet*.1994;344(8932):1273-1276.

Clemens JD et al. Misleading negative findings in a field trial of killed, oral cholera vaccine in Peru. *J Infect Dis*. 2001;183:1306-1308.

Taylor DN et al. Two-year study of the protective efficacy of the oral whole-cell plus recombinant B subunit cholera vaccine in Peru. *J Infect Dis*. 2000;181:1667-1673.

Lucas ME et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. *N Engl J Med*.2005;352(8):757-767.

Khatib AM et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. *Lancet Infect Dis*. 2012; 12(11): 837-844.

Peltola H et al. Prevention of travellers' diarrhoea by oral B- subunit/whole-cell cholera vaccine. *Lancet*. 1991;338 (8778):1285-1289.

Hill DR et al. Oral cholera vaccines: use in clinical practice. *Lancet Infect Dis*.2006;6:361-373.

Trach DD et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. *Lancet*. 1997; 25(349):231-235.

Wierzba TF et al. Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India. *Vaccine*. 2015;33(21):2463-2469.

Qadri F et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. *Lancet*. 2015;386(10001):1362-1371.

Ivers LC et al. Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis. *Lancet Glob Health*. 2015;3(3):e162-8.

Severe K et al. Effectiveness of Oral Cholera Vaccine in Haiti: 37-Month Follow-Up. *Am. J. Trop. Med. Hyg*. 2016; 94(5):1136-1142.

Azman AS et al. Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study. *Lancet Glob Health*. 2016;4:e856–63.

Qadri F et al. Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh. *New England Journal of Medicine*. 2016; 374(18):1723-1732.

Baik YO et al. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines. *Vaccine*. 2015; 33(46): 6360-6365.

Holmgren J et al. Oral B-subunit killed whole-cell cholera vaccine. In: Levine MM et al, eds. *New Generation Vaccines*. Third Edition. New York: Marcel Dekker, 2004.

Anh DD et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. *Vaccine*. 2007;25:1149-1155.

Mahalanabis D et al. A randomized, placebo controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. *PLoS One*. 2008; 3(6):e2323.

Saha A et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. *Vaccine*. 2011; 29(46): 8285-8295.

Sur D et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. *Lancet*. 2009; 374: 1694–1702

Desai SN et al. A randomized, double-blind, controlled trial to evaluate the safety and immunogenicity of killed oral cholera vaccine (Shanchol) in healthy individuals in Ethiopia. *Int J Infect Dis*. 2014; 93(3): 527–533

Phares C et al.. Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand. *Vaccine*. 2016; 34:128–133

Abubakar A et al. The first use of the global oral cholera vaccine emergency stockpile: lessons from South Sudan. *PLoS Med*. 2015;12(11): e1001901.

Bhattacharya SK et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. *Lancet Infectious Diseases*. 2013; 13(12):1050-1056.

Thiem VD et.al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. *Vaccine*.2006;24:4297-4303.

Grading table II (duration of protection). Conclusion: Although the duration of protection of currently licensed cholera vaccines varies with factors such as age at vaccination and biotype of prevailing *V. cholerae*, protection levels of >50% are not in general maintained for more than two years after vaccination.http://www.who.int/immunization/policy/position_papers/cholera_GRADE_evidence_recommendation_tables.pdf, accessed August 2017.

No abstract available.

Ali M et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. *Lancet*. 2005;366:44-49.

Longini IM et al. Controlling endemic cholera with oral vaccines. *PLoS Med*. 2007;4(11):e336.

Ali M et al. Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India. *Clin Infect Dis*. 2013; 56(8): 1123-1131.

von Seidlein L et al. Is HIV infection associated with an increased risk for cholera? Findings from a case-control study in Mozambique. *Trop Med Int Health*. 2008;13(5): 683-688.

Lucas ME et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. *New England J Med*. 2005; 352(8): 757-767.

Ivers LC et al. Immunogenicity of the bivalent oral cholera vaccine Shanchol in Haitian adults with HIV infection. *J Infect Dis*. 2015;212(5):779-783

Technical Note Evidence of the risks and benefits of vaccinating pregnant women with WHO pre-qualified cholera vaccines during mass campaigns.
http://www.who.int/cholera/vaccines/Risk_Benefits_vaccinating_pregnant_women_Technical_Note_13Jan2016.pdf, accessed May 2017.

No abstract available.

Hashim R et al. Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy. *PLoS Negl Trop Dis*. 2012; 6(7): e1743.

Grout L et al. Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study. *PLoS Negl Trop Dis*. 2015; 9(12): e0004274.

Ali M et al. Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort study. *Lancet Infect Dis*. 2017; 17(5):538–544.

Khan AI et al. Safety of the oral cholera vaccine in pregnancy: Retrospective findings from a subgroup following mass vaccination campaign in Dhaka, Bangladesh. *Vaccine*. 2017; 35(11): 1538-1543.

Poulet J. The 1832 cholera epidemic in the prisons of Paris. *La semaine des hopitaux*.1973; 49(41):2717-2722.

Bwire G et al. Nosocomial Cholera Outbreak in a Mental Hospital: Challenges and Lessons Learnt from Butabika National Referral Mental Hospital, Uganda. *Am J Trop Med Hyg*. 2015, 93(3):534–538

Kollaritsch H et al. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. *J Infect Dis*.1997;175(4):871-875.

Jeuland M et al. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs. *Vaccine*. 2009; 27(23): 3109-20.

Kim SY et al. Potential impact of reactive vaccination in controlling cholera outbreaks: an exploratory analysis using a Zimbabwean experience. *South African Medical Journal Suid-Afrikaanse Tydskrif Vir Geneeskunde*. 2011;101(9):659-6.

Kar SK et al. Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model. *PLoS Neglected Tropical Diseases*.2014; 8(2): e2629.

GRADE and Evidence to Recommendation

tables:http://www.who.int/immunization/policy/position_papers/cholera_GRADE_evidence_recommendation_tables.pdf, accessed August 2017.

No abstract available.

Oral Cholera vaccine stockpile for cholera emergency response.

http://www.who.int/cholera/vaccines/Briefing_OCV_stockpile.pdf?ua=1&ua=1, accessed April 2017.

No abstract available.

Vaccination in acute humanitarian emergencies: a framework for decision making.

Geneva, Switzerland: World Health Organization; 2017.

<http://apps.who.int/iris/bitstream/10665/255575/1/WHO-IVB-17.03-eng.pdf>,

accessed July 2017

No abstract available.